Undiscovered and Profitable Biotech with significant upside potential ..Many new attractive Product launches and approvals expected within this year .
Cipher Pharmaceuticals (CPH.T)
Market Cap: $39.7 Million CAD
Cash $10.4 Million CAD
Price: $1.46
Shares Out: 26.8 Million
Slide Presentation
filecache.investorroom.com
Cipher anticipates several key milestones in 2019 that will continue to enhance long term value, including:
Xydalba launch in first half of 2019
DTR-001 pre-clinical results in Q2 2019
Regulatory approval for plecanatide from Health Canada in Q4 2019
Regulatory approval for A-101 from Health Canada in Q4 2019
Top line results for MOB-015 Phase 3 study in North America expected in late Q4 2019
Largest Shareholder :
John Douglas Mull, MD 9,911,265
Grandeur Peak Global Advisors LLC 1,522,200
Taylor Asset Management, Inc. (Canada) 243,100
Harold Morton Wolkin, CFA 184,134
Arthur M. Deboeck 104,300
Mark A. Beaudet 87,790
Christian Godin 39,009
Robert D. Tessarolo 37,013
Stephen L. Lemieux, CPA 25,008
Acadian Asset Management LLC 9,093
 |
